Additionally, it promotes the expression of various bioactive molecules involved in inflammation and repair, such as CXCL8, hepatocyte growth factor, and CXCL1, suggesting that LL-37 or cathelicidin-derived mimetics could be used as a therapeutic option for treating periodontitis [65]. The gene discussed is CAMP; the disease is periodontitis.